BMS to Leverage Autolus’s Safety Switch
On Tuesday, October 4, Autolus announced (press release) that it has entered into an agreement with BMS. Under the agreement, BMS will be granted access to Autolus’s proprietary RQR8 safety switch, while Autolus will receive upfront and milestone payments. Below, Celltelligence provides insights on Autolus’s safety switch, while discussing how BMS could leverage RQR8.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.